{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"immunoglobulin G1, anti-human interleukin 6 receptor alpha) (human REGN88 heavy chain), disulfide with human REGN88 light chain, dimer"},{"type":"USBrandName","name":"Kevzara"},{"type":"CodeName","name":"REGN88"},{"type":"CodeName","name":"SAR153191"},{"type":"CASRegistryName","name":"1189541-98-7"}],"definition":{"html":"A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inflammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.","text":"A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inflammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation."},"drugInfoSummaryLink":null,"nciConceptId":"C152302","nciConceptName":"Sarilumab","termId":803539,"name":"sarilumab","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sarilumab"}],"links":null}